| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 6.278 | 8.861 | 13.616 | 11.795 | 9.443 | 8.755 | 13.055 | 11.591 | 29.245 | 10.596 |
| Total Income - EUR | 6.296 | 8.863 | 13.621 | 11.795 | 9.506 | 8.782 | 13.055 | 11.591 | 29.245 | 10.659 |
| Total Expenses - EUR | 2.486 | 7.463 | 12.428 | 12.649 | 14.739 | 12.203 | 10.657 | 13.923 | 27.215 | 18.326 |
| Gross Profit/Loss - EUR | 3.810 | 1.400 | 1.193 | -853 | -5.233 | -3.421 | 2.398 | -2.332 | 2.030 | -7.667 |
| Net Profit/Loss - EUR | 3.622 | 1.134 | 936 | -971 | -5.329 | -3.506 | 2.092 | -2.672 | 1.743 | -7.774 |
| Employees | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
Check the financial reports for the company - Nukdia Med Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.632 |
| Current Assets | 18.816 | 19.946 | 24.278 | 27.664 | 25.184 | 27.036 | 31.628 | 28.779 | 38.011 | 33.046 |
| Inventories | 2.866 | 3.388 | 3.615 | 3.771 | 4.158 | 7.269 | 7.183 | 7.006 | 4.329 | 5.315 |
| Receivables | 15.103 | 16.218 | 19.057 | 21.456 | 19.577 | 18.398 | 22.147 | 21.436 | 31.136 | 23.478 |
| Cash | 847 | 339 | 1.606 | 2.437 | 1.450 | 1.369 | 2.298 | 337 | 2.546 | 4.253 |
| Shareholders Funds | 15.070 | 16.050 | 16.714 | 15.436 | 9.808 | 6.116 | 8.073 | 5.426 | 7.153 | -660 |
| Social Capital | 45 | 45 | 44 | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | 3.746 | 3.896 | 7.565 | 12.228 | 15.376 | 20.920 | 23.555 | 24.786 | 32.286 | 36.759 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "4646 - 4646" | |||||||||
| CAEN Financial Year |
4646
|
|||||||||
Comments - Nukdia Med Srl